Tue, Sep 16, 2014, 10:17 AM EDT - U.S. Markets close in 5 hrs 43 mins


% | $
Quotes you view appear here for quick access.

NanoLogix Inc. Message Board

  • nmbr1stckpckr nmbr1stckpckr Mar 16, 2012 11:39 AM Flag

    the competition is working

    hard to try to get ahead in NNLX's market:


    (This PR does NOT relate to NNLX)

    "This rule would lower the current risk classification for nucleic acid-based tests allowing manufacturers to utilize the faster, more streamlined clearance pathway for medical devices."


    "Nucleic acid-based tests, which detect the genetic material of infecting bacteria, can shorten the time needed to diagnose TB disease from one to two weeks to one to two hours. When used in conjunction with other clinical tests, nucleic acid-based tests can result in earlier treatment, improved patient outcomes, and interrupt further spread of TB."

    The 2nd sentence above is interesting....why in conjunction with other clinical tests? Could they be referring to tests that determine whether the bacteria is alive or dead and whether the bacteria is resistant to antibodies?

    I wonder who the lobbyists are that are pushing the FDA with the initiative in the PR?

    My takeaway is that there is a lot of (inferior) competition out there who want a piece of the market. How big a splash NNLX makes when they enter the fray will depend largely on who champions their product. I am overjoyed that Battelle is our champion.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.090.00(+5.76%)9:33 AMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.